We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A Discrete Gene Signature Is a Diagnostic and Predictive Biomarker for Kidney Transplant Rejection

By LabMedica International staff writers
Posted on 15 Jul 2013
Print article
A genetic signature comprising two messenger RNA molecules that encode immune system proteins and one noncoding RNA molecule that participates in protein production has been shown to be diagnostic and prognostic of acute cellular rejection in kidney transplants.

The standard test for the diagnosis of acute rejection in kidney transplants is the renal biopsy. However, biopsy samples, in addition to being invasive with risk of infection, may not give the physician an accurate impression of the overall state of the kidney, since biopsy specimens are small and may not contain any injured tissue.

Investigators at the [US] National Institutes of Health (Bethesda, MD, USA) and colleagues at Weill Cornell Medical College (New York, NY, USA) and the University of Pennsylvania (Philadelphia, USA) sought a noninvasive test that would accurately detect or predict kidney transplant rejection.

To this end, they collected 4,300 urine specimens from 485 kidney-graft recipients from day three through month 12 after transplantation. Messenger RNA (mRNA) levels were measured in urinary cells taken from the samples and correlated with allograft-rejection status with the use of logistic regression.

The investigators found that a three-gene signature representing 18S ribosomal RNA (rRNA), CD3epsilon mRNA, and interferon-inducible protein 10 (IP-10) mRNA discriminated between biopsy specimens showing acute cellular rejection and those not showing rejection. The signature distinguished acute cellular rejection from acute antibody-mediated rejection and borderline rejection. It also distinguished patients who received anti-interleukin-2 receptor antibodies from those who received T-cell-depleting antibodies and was diagnostic of acute cellular rejection in both groups. Urinary tract infection did not affect the signature.

Levels of the signature RNAs in repeated urine samples remained below the diagnostic threshold for acute cellular rejection in the group of patients with no rejection, but in the group with rejection, there was a sharp rise during the weeks before a biopsy revealed signs of rejection.

"The test described in this study may lead to better, more personalized care for kidney transplant recipients by reducing the need for biopsies and enabling physicians to tailor immunosuppressive therapy to individual patients," said contributing author Dr. Nancy Bridges, transplantation branch chief at the [US] National Institutes of Health. "The National Institutes of Health-funded Clinical Trials in Organ Transplantation (CTOT) cooperative research consortium provided the infrastructure and collaborative environment needed to conduct the large, rigorous, multicenter study that established the efficacy of this biomarker-based test."

The study was published in the July 4, 2013, issue of the New England Journal of Medicine.

Related Links:

National Institutes of Health
Weill Cornell Medical College
University of Pennsylvania


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.